一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (666k)  required ID / password
Article in Japanese

Case Report

Two cases of pulmonary pleomorphic carcinoma successfully treated with platinum-based chemotherapy with pembrolizumab

Soichi Maruyamaa,b  Takafumi Suzukib  Yasuhisa Takanashia  Daichi Kondoa  Tomoshige Chiakia 

aDepartment of Respiratory Medicine, Hokushin General Hospital
bDepartment of Respiratory Medicine, Tokyo Medical and Dental University

ABSTRACT

Pulmonary pleomorphic carcinoma (PPC) is considered to be resistant to chemotherapy and radiotherapy. Here, we report two cases of PPC which were treated with pembrolizumab and platinum-based chemotherapy.
Case 1: A 64-year-old man visited our hospital with a chief complaint of dyspnea on exertion. Chest computed tomography (CT) showed a sizable tumor, 10 cm in diameter, in the right lower lobe. We conducted a CT-guided percutaneous biopsy, which indicated PPC (cT4N2M1a, cStage IV A). Although there was no expression of PD-L1, he was treated with pembrolizumab, carboplatin, and nab-paclitaxel as a first-line chemotherapy, which stabilized the disease.
Case 2: A 77-year-old man presented with dyspnea on exertion. CT showed a tumor less than 7 cm in diameter and atelectasis of the left lung. 18-fluorine fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) imaging showed gluteus medius muscle metastasis. We conducted a bronchoscopy and ultrasound guided biopsy, which revealed PPC (cT3N2M1b, cStage IV A) with a low expression of PD-L1 (tumor proportion score, 10%). He was treated with pembrolizumab, carboplatin, and paclitaxel as a first-line chemotherapy, which led to a partial response.

KEYWORDS

Pulmonary pleomorphic carcinoma (PPC)  Chemotherapy  Immune checkpoint inhibitor (ICI) 

Received 24 Jan 2021 / Accepted 19 Jul 2021

AJRS, 10(5): 415-420, 2021

Google Scholar